Those that have been in this stock for years are showing a very nice profit in their accounts and also see trial progression. The only ones down are those that bought near the highs last year as it ran up after Brilacidin was granted QIDP status from the FDA.
All stocks, especially, biotech have swings up and down. While it hurts to see an account down from the highs, it isn't correct to say there is nothing to show for the great pipeline. The stock may be down, but, the pipeline is progressing.
In Reply to 'BobbyKIrk'
Because Leo has shareholders sitting here for years with nothing to show from our great pipeline that we have .wait ,wait ,wait delay delay come on already .
Market Data 
Markets 
AI
